(Q44405540)

2 December 2017

title

Cytochrome P450 mediated-drug metabolism is reduced in children with sepsis-induced multiple organ failure (English)

1 reference

2 December 2017

0 references

Reginald F Frye

4

0 references

author name string

Joseph A Carcillo

1

1 reference

2 December 2017

Lesley Doughty

2

1 reference

2 December 2017

Danny Kofos

3

1 reference

2 December 2017

Sandra S Kaplan

5

1 reference

2 December 2017

Howell Sasser

6

1 reference

2 December 2017

Gilbert J Burckart

7

1 reference

2 December 2017

publication date

16 April 2003

1 reference

2 December 2017

published in

Intensive Care Medicine

1 reference

2 December 2017

volume

29

1 reference

2 December 2017

issue

6

1 reference

2 December 2017

page(s)

980-984

1 reference

Altered theophylline pharmacokinetics during acute respiratory viral illness

2 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00134-003-1758-3

Regulation of cytochromes P450 during inflammation and infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00134-003-1758-3

Hepatic drug metabolism and immunostimulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00134-003-1758-3

Endotoxin administration to humans inhibits hepatic cytochrome P450-mediated drug metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00134-003-1758-3

Endotoxin depresses hepatic cytochrome P450-mediated drug metabolism in women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00134-003-1758-3

The sepsis syndrome. Definition and general approach to management

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00134-003-1758-3

Mortality associated with multiple organ system failure and sepsis in pediatric intensive care unit

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00134-003-1758-3

Nitric oxide production in critically ill patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00134-003-1758-3

Studies on the different metabolic pathways of antipyrine in man. I. Oral administration of 250, 500 and 1000 mg to healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00134-003-1758-3

Quantifying hepatic function in the presence of liver disease with phenazone (antipyrine) and its metabolites

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00134-003-1758-3

Epidemiology of sepsis and multiple organ dysfunction syndrome in children

21 January 2018

1 reference

12 December 2020

Antipyrine as a probe for human oxidative drug metabolism: Identification of the cytochrome P450 enzymes catalyzing 4-hydroxyantipyrine, 3-hydroxymethylantipyrine, and norantipyrine formation*

1 reference

12 December 2020

Nitric oxide mediates hepatic cytochrome P450 dysfunction induced by endotoxin

1 reference

12 December 2020

Inflammatory cytokine and nitric oxide responses in pediatric sepsis and organ failure

1 reference

12 December 2020

[Multiple organ failure after severe trauma: predictable by the MEGX liver function test?]

1 reference

12 December 2020

Antipyrine clearance per unit volume liver: an assessment of hepatic function in chronic liver disease

1 reference

12 December 2020

Peroxynitrite-mediated nitration of tyrosine and inactivation of the catalytic activity of cytochrome P450 2B1

1 reference

12 December 2020

Cytokines down-regulate expression of major cytochrome P-450 enzymes in adult human hepatocytes in primary culture

1 reference

12 December 2020

Altered theophylline clearance during an influenza B outbreak

1 reference

12 December 2020

Plasma nitrite and nitrate concentrations and multiple organ failure in pediatric sepsis

1 reference

12 December 2020

Pharmacokinetics and metabolism of antipyrine (phenazone) after intravenous and oral administration.

1 reference

12 December 2020

Evaluation of the influence of diabetes mellitus on antipyrine metabolism and CYP1A2 and CYP2D6 activity

1 reference

12 December 2020

10.1007/S00134-003-1758-3

Identifiers

DOI

1 reference

2 December 2017

1 reference